Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy
NCT02139280
Completed
No prospective randomized trials have evaluated the most efficacious dose of cyclophosphamide to mobilize autologous stem cells. We previously demonstrated that the time to collection of autologous hematopoietic stem cells is 10-12 days following the one dose of cyclophosphamide and daily G-CSF (granulocyte-colony stimulating factor).9 This prospective randomized trial is designed to determine if a lower dose of cyclophosphamide (1.5 gm/m2) will be as efficacious as the intermediate dose (3 gm/m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2021
Locations: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Hematologic Malignancies
Register for Updates
SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
NCT03066947
Completed
This is a single arm, open label study of SV-BR-1-GM, a targeted immunotherapy for breast cancer. Eligible patients will have histological confirmation of breast cancer with recurrent and/or metastatic lesions. The treatment regimen includes a pre-treatment with low-dose cyclophosphamide 2-3 days before the inoculation; inoculation in 4 sites on the thighs and upper back; and post-treatment inoculation of Interferon-alpha-2b into the sites of inoculation \~2 and \~4 days after the inoculation. T... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/27/2021
Locations: St. Joseph Heritage Healthcare, Santa Rosa, California +4 locations
Conditions: Breastcancer, Breast Neoplasm
Register for Updates
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
NCT02032277
Completed
This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
01/15/2021
Locations: Scottsdale Healthcare /ID# 120473, Scottsdale, Arizona +157 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
NCT01554371
Completed
The purpose of this study is to test the safety of eribulin (Halaven™) and cyclophosphamide (Cytoxan®) given together at different doses. This study will look at what effects, good and/or bad, that these drugs have on solid tumors. Eribulin is a drug that has been approved by the FDA for breast cancer that has spread to other parts of the body. Cyclophosphamide has been approved for different types of cancers (including breast cancer). However, the combination of eribulin and cyclophosphamide is... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/14/2021
Locations: University of California, San Francisco, San Francisco, California
Conditions: Malignant Solid Tumour, Breast Cancer Nos Metastatic Recurrent, Neuropathy
Register for Updates
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
NCT02423915
Completed
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. T-cells are white blood cells that are important to the immune system. The T cells for this study (called regulatory T-cells, or Tregs) will be from a donor who is not related to you. Before the Tregs are given to you, they may be changed in the laboratory to make use of sugar that is found in small amounts in blood cells through a process called fucosylation. They are then called fucosylat... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/06/2021
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia, Lymphoma
Register for Updates
Stem Cell Transplantation for Stiff Person Syndrome (SPS)
NCT02282514
Terminated
Non-myeloablative regimens (as the investigators use herein) are designed to maximally suppress the immune system without destruction of the bone marrow stem cell compartment. When using a non-myeloablative regimen recovery occurs without infusion of stem cells and the stem cells are autologous. While not necessary for recovery, stem cell infusion may shorten the interval of neutropenia and attendant complications. Thus in reality there is no transplant only an autologous supportive blood produ... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/06/2021
Locations: Northwestern University, Chicago, Illinois
Conditions: Stiff-Person Syndrome
Register for Updates
Maximizing Outcome of Multiple Sclerosis Transplantation
NCT03342638
Terminated
Randomized study of autologous un-manipulated peripheral blood hematopoietic stem cell transplant (HSCT) comparing two regimens: (1) cyclophosphamide and rabbit anti-thymoglobulin (rATG) versus (2) cyclophosphamide, rATG, and Intravenous Immunoglobulin (IVIg).
Gender:
ALL
Ages:
Between 18 years and 58 years
Trial Updated:
01/06/2021
Locations: Northwestern University, Chicago, Illinois
Conditions: Multiple Sclerosis, Relapsing-Remitting
Register for Updates
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders
NCT00358657
Terminated
This phase I/II trial studies the side effects of fludarabine phosphate, cyclophosphamide and total-body irradiation followed by donor bone marrow transplant and cyclophosphamide, mycophenolate mofetil, tacrolimus, and sirolimus in treating patients with primary immunodeficiency disorders or noncancerous inherited disorders. Giving low doses of chemotherapy and total-body irradiation before a bone marrow transplant helps prepare the patient's body to accept the incoming donor's bone marrow and d... Read More
Gender:
ALL
Ages:
55 years and below
Trial Updated:
01/06/2021
Locations: The Children's Hospital at TriStar Centennial, Nashville, Tennessee +2 locations
Conditions: Immunodeficiency Syndrome, Severe Aplastic Anemia, Genetic Disorder
Register for Updates
Stem Cell Transplant for Hematological Malignancy
NCT00176930
Terminated
The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood. The protocol was revised to reflect that this study is considered "treatment guidelines", rather than a research study.
Gender:
ALL
Ages:
55 years and below
Trial Updated:
12/31/2020
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute, MDS, Leukemia, Lymphocytic, Chronic, JMML, Hodgkin's Disease, Non-hodgkin's Lymphoma, Multiple Myeloma
Register for Updates
A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer
NCT00210470
Completed
This was a Phase 2a trial to investigate the safety and biological activity of the RIX-2 Regimen in patients with untreated, resectable squamous cell cancer of the head and neck (HNSCC).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/10/2020
Locations: University of Alabama at Birmingham, Birmingham, Alabama +7 locations
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Bone Marrow Transplant in Treating Patients With Hematologic Cancers
NCT00005797
Completed
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying how well donor bone marrow transplant works in treati... Read More
Gender:
ALL
Ages:
Between 15 years and 55 years
Trial Updated:
12/09/2020
Locations: H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida
Conditions: Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Register for Updates
Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus
NCT00076752
Completed
This study will examine a new approach to treating patients with severe systemic lupus erythematosus (SLE) that involves collecting stem cells (cells produced by the bone marrow that develop into blood cells) from the patient, completely shutting down the patient's immune system, and then giving back the patient's stem cells. SLE is a chronic, inflammatory disorder of the immune system that can affect many organs. It is called an autoimmune disease because the patient's lymphocytes (white blood... Read More
Gender:
ALL
Ages:
Between 15 years and 40 years
Trial Updated:
12/09/2020
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Lupus Erythematosus, Systemic
Register for Updates